Federated Hermes, Inc. Satsuma Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $419 - $795	100 New	100 $1,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $1,830 - $2,751	-441 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $2,819 - $4,452	-621 Reduced 58.47%	441 $2,000
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $3,384 - $5,111	705 Added 197.48%	1,062 $7,000
Q1 2021 May 13, 2021	SELL	$4.57 - $7.18 $900 - $1,414	-197 Reduced 35.56%	357 $2,000
Q4 2020 Feb 12, 2021	BUY	$3.56 - $5.09 $1,972 - $2,819	554 New	554 $3,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.